Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA to Provide Tumor Profiling for Breast Cancer Patients

NEW YORK (GenomeWeb) – Belgium-based genomic testing company OncoDNA said today that it has agreed to supply tumor molecular profiling analysis for non-profit clinical research organization SOLTI's AGATA breast cancer screening program.

AGATA is a pilot genomic screening program pioneered by SOLTI in Spain that aims to refer breast cancer patients to clinical trials based on their tumor molecular profile. Under the terms of the agreement, OncoDNA will customize its OncoKDM (Knowledge Drive Medicine) software-as-a-service platform to answer the specific needs of the AGATA trial. This will include integrating three types of DNA data — Illumina NGS, Ion Torrent NGS, and analysis using Sequenom's Massarray — as well as RNA expression profiling and proteomic data.

OncoKDM will use these analyses to generate a theranostic report that can then be used to guide treatment in different clinical trials for breast cancer patients within the AGATA program.

"We are excited to work together to enhance the outcomes we provide through the AGATA program to better direct patients to clinical trials according to their tumor profile," said SOLTI President Eva Ciruelos in a statement. OncoDNA Chief Technology Officer Jean-François Laes added that the collaboration is the first the company has announced for OncoKDM.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.